First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor. - Gatlik, Ewa; Mehes, Beata; Voltz, Emilie; Sommer, Ulrike; Tritto, Elaine; Lestini, Giulia; Liu, Xiaoxi; Pal, Parasar; Velinova, Maria; Denney, Wiliam S.; Fu, Yunlin; Opipari, Anthony; et al. (CTS: Clinical & Translational Science, 2024)